Preclinical studies have indicated that pharmacological activation of Nrf2 may be a promising therapeutic approach for several chronic diseases associated with high levels of oxidative stress and inflammation, such as T2D, chronic kidney, cardiovascular and other metabolic diseases [8–11]. The gene discussed is NFE2L2; the disease is Other metabolic disease.